TEL AVIV, Israel , Sept. 14, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT),  a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced it will provide a corporate overview at the Cantor...

TEL AVIV, Israel , Aug. 28, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced it will provide a corporate overview at the 19th Annual...

Conference Call and Webcast at 8:30am Eastern Time Today TEL AVIV, Israel , Aug. 14, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), announced financial results for the three and six months ended June 30, 2017 and provided a corporate update....

TEL AVIV, Israel , Aug. 02, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast...

Data to be Presented at 2017 BIO International Convention in San Diego, CA TEL AVIV, Israel , June 19, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) provided an update on the long term status and survival of patients from three completed Phase 2 trials, which investigated the company’s...

Industry leader with extensive oncology experience joins company as VB-111 advances toward registration TEL AVIV, Israel , June 15, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) today announced the appointment of Corinne Epperly, MD, MPH, as U.S. Chief Operating Officer. Dr....

Update on Long term Survival of VB-111 Treated Patients to be Presented at BIO on June 20 TEL AVIV, Israel , June 14, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) today announced Prof. Dror Harats , CEO,  will provide a corporate overview at the 2017 BIO International Convention in San...

TEL AVIV, Israel , June 08, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) today announced that it has been awarded a grant of 8.75 million New Israeli Shekels (approximately $2.5 million ) by the Israel Innovation Authority .  The grant will support clinical trials and development...

TEL AVIV, Israel , June 05, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), today announced the presentation of new data demonstrating that treatment with VB-111 (ofranergene obadenovec) induced durable tumor regression and attenuation of tumor growth in patients with recurrent...

TEL AVIV, Israel , May 15, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, announced financial results for the first quarter ended March 31, 2017 , as...